Pulmonx (NASDAQ:LUNG – Get Free Report) and SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) are both small-cap medical companies, but which is the superior business? Get Pulmonx alerts:Analyst RatingsThis is a summary of recent ratings and recommmendations for Pulmonx and SOPHiA GENETICS, as reported by MarketBeat. Given Pulmonx’s stronger consensus rating and higher probable upside, research analysts clearly believe Pulmonx is more favorable than SOPHiA GENETICS. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulmonx $83.79 million 0.85 -$56.39 million ($1.41) -1.22 SOPHiA GENETICS $65.17 million 5.36 -$62.49 million ($0.46) -11.24Pulmonx has higher revenue and earnings than SOPHiA GENETICS. Net Margins Return on Equity Return on Assets Pulmonx -61.91% -77.58% -37.90% SOPHiA GENETICS -41.13% -37.75% -18.75%SummaryPulmonx beats SOPHiA GENETICS on 8 of the 14 factors compared between the two stocks.